Titan Biotech (BOM:524717) Other Current Payables: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524717 Titan Biotech Ltd BOM:524717
53 GF Score
Price ₹407.05
GF Value ₹146.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Titan Biotech Other Current Payables?

Titan Biotech BOM:524717 +1.08% 53 Other Current Payables is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:524717 with a GF Score™ of 53/100 and a GF Value™ of ₹146.15 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Titan Biotech's Other Current Payables for the quarter that ended in Mar. 2026 was ₹0 Mil.

Titan Biotech's annual Other Current Payables increased from Mar. 2024 (₹65 Mil) to Mar. 2025 (₹70 Mil) but then declined from Mar. 2025 (₹70 Mil) to Mar. 2026 (₹0 Mil).

Titan Biotech Other Current Payables Related Terms

Titan Biotech Other Current Payables Historical Data

* Premium members only.

The historical data trend for Titan Biotech's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Biotech Other Current Payables Chart

Titan Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 52.19 64.77 69.53 0.00

Titan Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.53 0.00 0.00 0.00 0.00
BOM:524717
53GF Score
Titan Biotech Ltd BOM:524717
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Biotech Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹0 Mil mean?
Titan Biotech (BOM:524717) has a Other Current Payables of ₹0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Titan Biotech and its competitors.
Is Titan Biotech's Other Current Payables too high?
Titan Biotech's current Other Current Payables is ₹0 Mil. Overall, Titan Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Other Current Payables compare to VRTX and REGN?
Titan Biotech's Other Current Payables of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Titan Biotech and its competitors. Titan Biotech's current Other Current Payables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹146.15, compared to a current price of ₹407.05 — trading 178.5% above its estimated fair value. The current Other Current Payables is ₹0 Mil. Titan Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Other Current Payables is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Titan Biotech (BOM:524717) Overvalued in 2026?

Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued. The current stock price of ₹407.05 is trading 178.5% above its estimated GF Value™ of ₹146.15. GuruFocus considers Titan Biotech to be Significantly Overvalued.

Key valuation signals for BOM:524717:

  • Other Current Payables: ₹0 Mil
  • GF Value™: ₹146.15 vs. price of ₹407.05 (178.5% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Titan Biotech Business Description

Address Netaji Subhash Place, 903-909, 9th Floor, Bigjos Tower, New Delhi, IND, 110034
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
53GF Score

Get the complete analysis for BOM:524717

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹407.05
Price
₹146.15
GF Value